CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 200 target
Drug / intervention
Traditional Chinese Medicine Formulation +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04403529
NCT04403529Phase 3Unknown
CompareCT.gov

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Fudan University·interventional·Posted May 27, 2020·Updated Jun 1, 2020

In Brief

A Phase 3 clinical trial evaluating Traditional Chinese Medicine Formulation and Placebo Formulation for Triple Negative Breast Cancer. Targeting 200 participants across 1 site.

Detailed Summary

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Cancer
CountriesChina
Collaborators--

Timeline

Phase 3UnknownOverdue
202120222023202420252026
First PostedMay 27, 2020
Enrollment StartMay 25, 2020
Primary CompletionMay 31, 2024
TodayJul 1, 2026
Enrollment to primary: 4.0 yearsPosted 6.1 years ago

Interventions

Traditional Chinese Medicine Formulationdrug

The "prescription for breast cancer" Traditional Chinese Medicine formulation is a combination of 12 herbal components and it is available in granules form to be dissolved in hot water for consumption.

Placebo Formulationdrug

Placebo granules contains 5% "prescription for breast cancer" Traditional Chinese Medicine formulation and 95% filler, it is available in granules form to be dissolved in hot water for consumption.